Oncology News | pharmaphorum

News

Reitsberger Hof Originalbild unter: http://xaver.fotograf.de/photo/5803d868-7d30-46c9-9bef-33690a5581f6

Morphosys to take on CAR-Ts in NHL with promising antibody

Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a common form of non-Hodgkin lymphoma, saying that the phase 2 t

News

After years of delays, NICE backs Celgene's Revlimid in firs...

After years of delays caused by wrangling over price, NICE has recommended regular NHS funding for Celgene’s Revlimid in combination with dexamethasone, as an option for certain adults with

News

CRUK tests drug combo for advanced pancreatic cancer

Cancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in advanced pancreatic cancer as part of its Combinations Alliance.<

News

Roche and AbbVie’s Venclexta approved in CLL

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lympho

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J unveils top pipeline prospects, with main focus on cance...

Johnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans to file 10 major drugs between now and 2023.

News

Merck and Pfizer's Bavencio approved for renal cell carcinom...

Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of

Morphosys to take on CAR-Ts in NHL with promising antibody

After years of delays, NICE backs Celgene's Revlimid in firs...

CRUK tests drug combo for advanced pancreatic cancer

Roche and AbbVie’s Venclexta approved in CLL

J&J unveils top pipeline prospects, with main focus on cance...

Merck and Pfizer's Bavencio approved for renal cell carcinom...

Datroway joins Trodelvy for frontline TNBC in the EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks